Arvinas and Pfizer Announce PROTACĀ® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Go back to Arvinas and Pfizer Announce PROTACĀ® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
(NASDAQ: ARVN) Delayed: 7.74 +0.07 (0.91%)
Previous Close $7.67    52 Week High
Open $7.70    52 Week Low
Day High $7.76    P/E N/A 
Day Low $7.48    EPS
Volume 711,055       

Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 40,693,972       

Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 40,693,972